Skip to main content
[Preprint]. 2026 Jan 27:2025.12.04.692214. Originally published 2025 Dec 6. [Version 2] doi: 10.64898/2025.12.04.692214

Figure 2: TCE monotherapy rejects tumors with high antigen density but fails to control those with low antigen density.

Figure 2:

(A) Experimental overview. C57BL/6 mice were injected subcutaneously (s.c.) with either high antigen density or low antigen density tumor cell lines followed by TCE monotherapy.

(B) 1 x 106 MC38int cells transduced to express high levels of TRP2 were grafted s.c. onto C57BL/6 mice in Matrigel, TRP2 TCE monotherapy (10 mg/kg q2d) or vehicle control (HBS) was started on day 2 (arrow) after tumor grafting. (p<0.0001, linear mixed-effect modeling) (n=10 mice per group).

(C) Fraction of mice with tumors < 500 mm3 during treatment with TRP2 TCE or control (HBS).

(D) 0.5 x 106 B16F10 (TRP2 low) were injected s.c. into C57BL/6 mice, TRP2 TCE monotherapy (q2d) or vehicle control (HBS) at the indicated doses was started on day 2 after tumor grafting (HBS: n=6; 5 mg/kg TRP2 TCE: n=6; 10 mg/kg TRP2 TCE n=7 mice). Arrow indicates treatment start. Tumor growth rates were not significantly different between groups (linear mixed-effect modeling).

(E) Number of tumor-infiltrating T cells / mg tumor in tumors from mice treated in (D).

(F) 0.5 x 106 16T SCLC cells (DLL3 high) were injected s.c. into B6129SF1/J mice in Matrigel and treated with 5 mg/kg DLL3 TCE or HBS q4d, arrow indicates treatment start (p = 0.0012, linear mixed-effect modeling; HBS: n=3 mice; DLL3 TCE: n=5 mice).

(G) Fraction of mice treated in (F) with tumor sizes < 1200 mm3.

(H) 0.5 x 106 KP1 SCLC cells (DLL3 low) were injected s.c. into B6129SF1/J mice in Matrigel and treated with the indicated doses of DLL3 TCE or HBS q4d, arrow indicates treatment start. Tumor growth rates were not significantly different between groups (linear mixed-effect modeling; HBS: n=5; 2 mg/kg DLL3 TCE: n=8; 5 mg/kg DLL3 TCE: n=10; 10 mg/kg DLL3 TCE: n=8 mice).

(I) Number of tumor-infiltrating T cells / mg tumor in tumors from mice treated in (H).

(J) Expression of H2-Kb on tumor cells from control or DLL3 TCE-treated mice was measured by flow cytometry as an indicator of TCE-induced IFNγ secretion by T cells. Comparison of means in (E), (I), (J): Student’s t-test; *: p ≤ 0.05, **: p ≤ 0.01, ***: p ≤ 0.001, ****: p ≤ 0.0001.

See also Supplemental Figure S2.